| First Author | Suckow MA | Year | 2004 |
| Journal | Cancer Lett | Volume | 209 |
| Issue | 2 | Pages | 165-9 |
| PubMed ID | 15159018 | Mgi Jnum | J:90679 |
| Mgi Id | MGI:3044455 | Doi | 10.1016/j.canlet.2004.01.007 |
| Citation | Suckow MA, et al. (2004) The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett 209(2):165-9 |
| abstractText | Ranolazine was shown to improve exercise parameters in patients with chronic angina. It works by switching myocardial energy metabolism from fatty acids to glucose, thus increasing the efficiency of ATP production under hypoxic conditions. Tumors are hypoxic and may also respond to ranolazine. We found that ranolazine caused a dose-dependent increase in tumor number in APC(Min/+) mice, a model of spontaneous intestinal tumorigenesis. Tumors from drug-treated mice were also more dysplastic and invasive than those from untreated mice. These findings have implications for the use of ranolazine in patients with a history of malignant neoplasms or adenomatous polyps. |
